Roche: A so-far-ignored asset reports encouraging phase II results

NEUTRAL, Fair Value CHF252 (+5%)

News published on August Wednesday 28, 2013
Share on

At the American Society of Retina Specialists (ASRS) today will be presented the first results from the phase II MAHALO study which investigates the anti-factor D lampalizumab (RG7417) in so-called geographic atrophy secondary to AMD. Part 1 of the study tested monthly and every other month intravitreal injections whereas part 2 compared the active drug to a sham injection.

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities